InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.02%
)
US TECH 100
20,490.00
(
-0.13%
)
Dow Jones
43,958.19
(
0.11%
)
Brent Oil
72.08
(
0.30%
)
Bitcoin
89,983.15
(
-0.65%
)
Post# of 253594
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rogerm

Send PM Follow Ignore
Followers 2
Posts 112
Boards Moderated 0
Alias Born 08/04/2005

rogerm

Re: jq1234 post# 191180

Tuesday, 05/12/2015 8:38:22 PM

Tuesday, May 12, 2015 8:38:22 PM

Post# of 253594
GLPG might be interested in CNCE's deuterated Ivacaftor as a shortcut. It is a QD version which may be an advantage over the BID Kalydeco. Tung the ceo of CNCE was responsible for developing Kalydeco when he previously worked at VRTX. He started a P1 for d-1va after CNCE issued a d-corrector patent in 2014. GLPG has 5 correctors in its pipeline and I thought the FDA panel today was clearly not impressed by VRTX's corrector (Lumacaftor) effectiveness.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up